title: Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
abstract: We randomized 21 patients with low-risk myelodysplastic syndromes (MDS) to receive a single subcutaneous bolus of recombinant erythropoietin (epoietin) +/- granulocyte-colony stimulating factor (G-CSF), or placebo and monitored erythropoietic response over 7 days. In this small study, the reticulocyte response at day 7 was highly predictive of subsequent response to a therapeutic trial of epoietin + G-CSF.
authors: David
authors: D
authors: Bowen
authors: Ann
authors: A
authors: Hyslop
authors: Norene
authors: N
authors: Keenan
authors: Michael
authors: M
authors: Groves
authors: Dominic
authors: D
authors: Culligan
authors: Peter
authors: P
authors: Johnson
authors: Ann
authors: A
authors: Shaw
authors: Fiona
authors: F
authors: Geddes
authors: Patricia
authors: P
authors: Evans
authors: John
authors: J
authors: Porter
authors: Ivor
authors: I
authors: Cavill